Tag: big pharma
-
Medexus Pharmaceuticals (MDP.V), poised for flight on the Nasdaq (coming soon)
If you are like me and health sciences is your sector of choice when it comes to investing in the markets, you’d better be very patient, love doing research – and a willingness to see it through!!! A sector famous for its high-risk-high-reward characteristics is definitely not recommended for the faint of heart. Lucky for…
-
Can scrappy Valeo Pharma (VPH.C) win a Stanley Cup?
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
-
![That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster]()
That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster
“There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system,” stated Pierre Laurin, CEO of Ingenew, who added that it could “potentially fight off symptoms associated with coronaviruses.”
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
![Sprint (S.NYSE), T-Mobile (TMUS.Q) gain $41 billion after gullible judge gives thumbs up to mega-merger]()
Sprint (S.NYSE), T-Mobile (TMUS.Q) gain $41 billion after gullible judge gives thumbs up to mega-merger
Judge Marrero said that opposing states “failed to persuade him that a merger of the No. 3 and 4 carriers would harm consumers”.
-
![Indignant Pharma CEO explains why the Lower Drug Costs Now Act is a terrible thing]()
Indignant Pharma CEO explains why the Lower Drug Costs Now Act is a terrible thing
“Americans spend more on prescription drugs than anyone else in the world,” states Bloomberg, “It’s true that they take a lot of pills. But what really sets the U.S. apart from most other countries is high prices.” Cancer drugs in the U.S. routinely cost $10,000 a month. The cost for old drugs has spiked, as…
-
![Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer?]()
Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer?
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth a combined $5.2 billion. Merck (MRK.NASDAQ) agreed to buy ArQule (ARQL.NASDAQ) for $2.7 billion, while French drug giant Sanofi (SNY.NASDAQ) agreed to purchase Synthorx (THOR.NASDAQ) for $2.5 billion. MRK has…
-
Biogen (BIIB.NASDAQ) and the brain death of big pharma
Ever since the greasy arrogant squirrel-faced grin of Martin Shkreli turned our collective stomach, big pharma has come under fire for their pricing practices. Pharma execs, often paid up to 300 times more than their average employee, shot back that research and development costs were crippling and all that needed to be paid for with…
-
The end of the world, or, how I learned to live with a habitually shrinking PMI
The Institute of Supply Management (ISM) U.S. manufacturing survey was released yesterday and, boy, did it ever raise alarms. Estimations of the ongoing U.S.-China trade war have been on a piecemeal basis up until now: It is common knowledge American soybean farmers are struggling, but calculating the material effects on U.S. business as a whole…
